MX2010001581A - Hidantoinas substituidas. - Google Patents

Hidantoinas substituidas.

Info

Publication number
MX2010001581A
MX2010001581A MX2010001581A MX2010001581A MX2010001581A MX 2010001581 A MX2010001581 A MX 2010001581A MX 2010001581 A MX2010001581 A MX 2010001581A MX 2010001581 A MX2010001581 A MX 2010001581A MX 2010001581 A MX2010001581 A MX 2010001581A
Authority
MX
Mexico
Prior art keywords
compounds
mek
substituted hydantoins
enzymes
cancer
Prior art date
Application number
MX2010001581A
Other languages
English (en)
Inventor
Norman Kong
Nicholas John Silvester Huby
Shaoqing Chen
John Anthony Moliterni
Omar Jose Morales
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010001581A publication Critical patent/MX2010001581A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Esta invención se refiere a los compuestos e la fórmula (1) o a las sales de los mismos farmacéuticamente aceptables, en donde R1, R2, R3, R4, R5 y R6 son descritos en esta solicitud. Estos compuestos inhiben las enzimas MEK 1 y MEK 2, que son proteínas cinasas que son componentes de la ruta de transducción de la señal de la MAP cinasa. Como tales, los compuestos tienen una actividad celular anti-hiperproliferativa y por consiguiente son útiles en el tratamiento de los trastornos proliferativos celulares, tales como el cáncer.
MX2010001581A 2007-08-16 2008-08-06 Hidantoinas substituidas. MX2010001581A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95614507P 2007-08-16 2007-08-16
PCT/EP2008/060326 WO2009021887A1 (en) 2007-08-16 2008-08-06 Substituted hydantoins

Publications (1)

Publication Number Publication Date
MX2010001581A true MX2010001581A (es) 2010-03-15

Family

ID=39830023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001581A MX2010001581A (es) 2007-08-16 2008-08-06 Hidantoinas substituidas.

Country Status (12)

Country Link
US (1) US7557221B2 (es)
EP (1) EP2188276B1 (es)
JP (1) JP2010536723A (es)
KR (1) KR101147583B1 (es)
CN (1) CN101778839A (es)
AT (1) ATE551336T1 (es)
AU (1) AU2008288556A1 (es)
BR (1) BRPI0815180A2 (es)
CA (1) CA2695956A1 (es)
ES (1) ES2383927T3 (es)
MX (1) MX2010001581A (es)
WO (1) WO2009021887A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
MY193562A (en) * 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
CA2926571C (en) * 2013-10-08 2022-05-17 Qing-bin LU Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
PL3169361T3 (pl) 2014-07-15 2019-11-29 Hoffmann La Roche Kompozycje do leczenia nowotworu z użyciem związków antagonistycznych wiązania osi pd-1 i inhibitorów mek

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001426A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
KR19990012061A (ko) 1997-07-26 1999-02-25 성재갑 파네실 전이효소 저해제로 유용한 하이덴토인 유도체
BR0110492A (pt) * 2000-05-03 2003-04-08 Hoffmann La Roche Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
JP2007523929A (ja) * 2004-02-26 2007-08-23 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ベンズイミダゾリル誘導体
KR100889721B1 (ko) 2004-08-17 2009-03-23 에프. 호프만-라 로슈 아게 치환 히단토인
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins

Also Published As

Publication number Publication date
EP2188276B1 (en) 2012-03-28
ATE551336T1 (de) 2012-04-15
US20090048452A1 (en) 2009-02-19
WO2009021887A1 (en) 2009-02-19
CA2695956A1 (en) 2009-02-19
BRPI0815180A2 (pt) 2019-09-24
US7557221B2 (en) 2009-07-07
AU2008288556A1 (en) 2009-02-19
EP2188276A1 (en) 2010-05-26
JP2010536723A (ja) 2010-12-02
KR101147583B1 (ko) 2012-05-21
ES2383927T3 (es) 2012-06-27
CN101778839A (zh) 2010-07-14
KR20100031777A (ko) 2010-03-24

Similar Documents

Publication Publication Date Title
WO2006120573A3 (en) Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
IS6501A (is) Pyrrólafleiður 2-indólínón prótín kínasa hindra
EA200970557A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
EA201100450A1 (ru) Макроциклические пирамидины в качестве ингибиторов протеинкиназы
MX2008001538A (es) Aril piridinas y metodos para su uso.
TW200801008A (en) Protein kinase inhibitors
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
UA95244C2 (ru) Соединения и способ модулирования активности киназ, и показания для их применения
WO2007123892A3 (en) Raf inhibitors and their uses
ZA200702645B (en) Diaminotriazole compounds useful as protein kinase inhibitors
MY153727A (en) Pyridazinone derivatives
SG179430A1 (en) Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
PH12014501355A1 (en) Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
MY149957A (en) Heterocyclic inhibitors of mek and methods of use thereof
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
NZ596571A (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
MX2010001581A (es) Hidantoinas substituidas.
BRPI0512547A (pt) pirimidinas

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration